logo
Women who don't give birth live longer: medical professor's remark sparks controversy

Women who don't give birth live longer: medical professor's remark sparks controversy

Korea Herald08-05-2025

Public opinion split between accurate depiction of burden of childbirth and criticism of discouraging women from having kids
South Korean medical professor Yoo Seong-ho's recent claim on the supposed trade-offs between longevity and multiple childbirths have sparked a controversy here, with some complaining that the comment disparages women from giving birth.
Yoo, a professor of forensic medicine at Seoul National University College of Medicine, said in a YouTube video on his channel, Deadmantalk, that statistically, women who give multiple births have shorter lifespans whereas women who never gave birth age less.
"It is true that women who give birth multiple times die at (relatively) earlier ages," he said in the video posted on his channel, after which he added that women who never gave birth do not age as much as women who did.
When lawyer Seo Hye-jin, a female panelist in the video, said not being married may be a bigger factor in women aging less, Yoo reiterated that childbirth is the biggest factor and it is "the most critical."
Yoo's remarks have sparked a heated debate online, with many internet users responding with anecdotal accounts of women who gave birth to multiple children and went on to live long, healthy lives. Some critics argued that such comments could discourage women from having children, which is "inappropriate" given South Korea's ongoing struggle with its chronically low birthrate.
South Korea's total fertility rate -- the number of children a woman is expected to have in her lifetime -- was 0.75 in 2024, the lowest among the members of the Organization for Economic Cooperation and Development.
Other commenters said that the medical professional was just emphasizing the significant physical toll childbirth can take on the body.
Does giving birth actually hurt life expectancy?
While many believe that going through immense pain and burden of childbirth is detrimental to a woman's lifespan and health, the trade-off between being a parent and living long has not yet been proven.
It is scientifically proven that pregnancy, childbirth and lactation demand a significant amount of extra energy, along with the obvious fact that labor is characterized by a very high level of pain.
Researchers of Kent State University in Ohio found evidence pregnancy was associated with accelerated aging among Filipina women due to energy allocation of the body toward fecundity, in the study "A life for a (shorter) life: The reproduction–longevity trade-off." The energy spent on reproduction increases the chance of offspring survival, but minimization of somatic maintenance accelerates biological aging on the mother's part.
But other reports based on census data have indicated that having children actually increases women's lifespans, for example the research "Payback time? Influence of having children on mortality in old age" by researchers from the Karolinska Institutet in Stockholm and Stockholm University.
The study of the general population in Sweden showed that both men and woman with at least one child experienced lower death risks than men and women without children, which was also the case when effect of having a partner was taken into account.
The Swedish state also provides generous support for raising children, such as universal subsidized child care and paid parental leave of 480 days per child to be shared by both parents.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

[팟캐스트] (694) 쏟아지는 대선 공약, 위기인구 대책은 어디에?
[팟캐스트] (694) 쏟아지는 대선 공약, 위기인구 대책은 어디에?

Korea Herald

time2 days ago

  • Korea Herald

[팟캐스트] (694) 쏟아지는 대선 공약, 위기인구 대책은 어디에?

진행자: 최정윤, Devin Whiting Clock is ticking, but demographic crisis gets drowned out in presidential race 기사 요약: 이른 대선을 앞두고 대통령 후보들이 여러 공약을 선보였던 가운데, 저출산과 초고령 사회로의 진입 등 한국의 심각한 인구 위기에 대한 공약이 부족하다는 의견 많아 [1] The compounding challenges of South Korea's low birth rate and the onset of a super-aged society have drawn little focus on the presidential campaign trail for the June 3 presidential election. The numbers alone underscore the urgency of strategically and systemically confronting the demographic crisis. compounding: 복합적인 onset: 시작 [2] South Korea's fertility rate was recorded at 0.75 in 2024, meaning the average South Korean woman is expected to have fewer than one child in her lifetime. Still, the country found a sliver of relief in the data, as 2024 marked the first time in nine years that the birth rate had not declined. sliver: 조각 [3] At the same time, however, the nation officially transitioned into a 'super-aged society' in December 2024 — a milestone that arrived earlier than expected. Observers called for a more holistic approach to devising campaign promises that tackle these demographic challenges, saying the next five years would be crucial to determining the country's fate. They warned that South Korea might otherwise be plagued by a range of social problems: the demise of remote rural areas, a workforce shortage, weaker military strength and a pension fund crisis, among other things. milestone: 중요한 단계 holistic: 전체적인 plague: 괴롭히다, 성가시게 하다 /전염병 demise: 종말, 죽음 기사 원문: [코리아헤럴드 팟캐스트 구독] 아이튠즈(아이폰): 네이버 오디오 클립(아이폰, 안드로이드 겸용):

GC Biopharma's Phase 3 Clinical Trial Results for Hunterase Published in SCIE-Indexed Journal
GC Biopharma's Phase 3 Clinical Trial Results for Hunterase Published in SCIE-Indexed Journal

Korea Herald

time7 days ago

  • Korea Herald

GC Biopharma's Phase 3 Clinical Trial Results for Hunterase Published in SCIE-Indexed Journal

YONGIN, South Korea, May 30, 2025 /PRNewswire/ -- GC Biopharma, a South Korean pharmaceutical company, announced that the Phase 3 clinical trial results for Hunterase (idursulfase beta), its investigational drug for Hunter Syndrome (MPS II), have been published in Genetics in Medicine, an SCIE-indexed journal. Conducted at Samsung Medical Center, the Phase 3 clinical trial enrolled 24 newly diagnosed Hunter Syndrome patients with no prior treatment. It evaluated the efficacy and safety of Hunterase over a one-year treatment period. Hunter Syndrome is a rare genetic disorder caused by a deficiency of iduronate-2-sulfatase (IDS), an enzyme critical for glycosaminoglycan (GAG) catabolism. This deficiency leads to the progressive accumulation of GAGs in various organs and tissues, resulting in multisystemic dysfunction, including joint stiffness and hepatosplenomegaly. The clinical trial results demonstrated that Hunterase significantly enhanced functional mobility, reduced urinary GAG concentrations, and markedly alleviated hepatosplenomegaly. In the 6-Minute Walk Test (6-MWT), the primary endpoint of the study, patients treated with Hunterase walked an average of 62.2 meters more after treatment. This improvement was more than eight times greater compared to the placebo group, which saw an average increase of just 7.3 meters. The 6-MWT measures the distance a patient can walk on a flat surface within 6 minutes. It is a widely used clinical measure for evaluating functional mobility, cardiopulmonary function, muscle strength, and overall physical health. In the context of Hunter syndrome, it serves as a standardized and meaningful indicator of disease progression and quality of life. In addition to the primary endpoint, the study also achieved positive outcomes in secondary endpoints, including changes in urinary total glycosaminoglycan (GAG) levels, as well as heparan sulfate (HS) and dermatan sulfate (DS) levels. The GAG levels decreased by 71%, while HS and DS levels decreased by 89% and 88%, respectively. Moreover, liver and spleen volumes were reduced by 27% and 26%, respectively, demonstrating the drug's effectiveness in addressing organ enlargement commonly associated with the disease. Hunterase also demonstrated a favorable safety profile. Most adverse events were mild or moderate, and no patients discontinued treatment due to side effects. Notably, only 19% of the patients had neutralizing antibodies detected three or more consecutive times, which is significantly lower than the 62.5% observed with the existing treatments. This suggests that Hunterase may offer a more sustained therapeutic effect compared to other currently available therapy. "This clinical trial is especially meaningful as it represents the first Phase 3 study in Asian patients to validate the clinical efficacy of Hunterase", said Professor Young Bae Sohn of Ajou University School of Medicine and Ajou University Hospital, the journal's first author. "The results showed significant clinical improvement not only in metabolic markers but also in organ size normalization and restoration of physical mobility." "We are thrilled to publish our encouraging phase 3 clinical trial results", stated Jae Uk Jeong, Head of R&D at GC Biopharma. "Hunterase, developed in Korea using our proprietary technology, has the potential to significantly improve the lives of patients with Hunter syndrome." Hunter Syndrome is an X-linked lysosomal storage disorder, affecting approximately 1 in 100,000 male births. In severe cases, the patients experience early death before they reach adulthood, highlighting the need for early diagnosis and treatment. Currently, two treatments are widely available worldwide for Hunter Syndrome: GC Biopharma's Hunterase and Takeda's Elaprase. About GC Biopharma GC Biopharma (formerly known as Green Cross Corporation) is a biopharmaceutical company headquartered in Yong-in, South Korea. The company has over half a century of experience in the development and manufacturing of plasma derivatives and vaccines, and is expanding its global presence with successful US market entry of Alyglo™(intravenous immunoglobulin G) in 2024. In line with its mission to meet the demands of future healthcare, GC Biopharma continues to drive innovation by leveraging its core R&D capabilities in engineering of proteins, mRNAs, and lipid nanoparticle (LNP) drug delivery platform to develop therapeutics for the field of rare disease as well as I&I (Immunology & Inflammation). To learn more about the company, visit This press release may contain biopharmaceuticals in forward-looking statements, which express the current beliefs and expectations of GC Biopharma's management. Such statements do not represent any guarantee by GC Biopharma or its management of future performance and involve known and unknown risks, uncertainties, and other factors. GC Biopharma undertakes no obligation to update or revise any forward-looking statement contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule.

Watchful of summer COVID-19 resurgence, Korea urges older adults to get vaccinated
Watchful of summer COVID-19 resurgence, Korea urges older adults to get vaccinated

Korea Herald

time30-05-2025

  • Korea Herald

Watchful of summer COVID-19 resurgence, Korea urges older adults to get vaccinated

The South Korean government is closely monitoring COVID-19 resurgences in regional neighbors including Hong Kong, China and Thailand, amid growing worries that a summer resurgence may hit the country again this year. At a Central Disaster and Safety Countermeasures Headquarters meeting Friday, Director Lee Han-kyung warned of worsening COVID-19 trends abroad. "In regions close to us — Hong Kong, China and Thailand — COVID-19 infections are rising, and this is a cause for concern," Lee said at the meeting. He urged senior citizens aged 65 and above, as well as residents in high-risk facilities, to get vaccinated, stressing that vaccination is key to preventing severe illness and death. According to government data, recent overseas COVID-19 cases are showing a noticeable uptick. In Hong Kong, confirmed cases for the week of May 11 to 17 totaled 977, exceeding the country's previous summer peak of 796. China's rate of positivity COVID-19 test results is steadily climbing toward last year's peak of 21.1 percent, while in Thailand, more than 65,000 new cases were reported in the three weeks following the Songkran holiday in April. Despite the global trend, the number of new COVID-19 cases in Korea remained at around 100 each week over the past month. Currently, South Korea estimates the number of confirmed cases in select hospitals on a weekly basis. Still, the government is taking a proactive stance in consideration that domestic cases last year surged sharply from late July to mid-August. Weekly confirmed cases jumped from 456 in the fourth week of July to over 1,400 by mid-August in 2023. To mitigate potential risks, health authorities have extended the vaccination period for high-risk groups until June 30, two months beyond the initial April 30 deadline. The Korean Medical Association also issued a public advisory, pointing to the seasonal temperature shifts, increased domestic and international travel and a noticeable drop in personal hygiene practices such as hand-washing. It recommended six precautionary measures: maintaining personal hygiene, wearing masks, prompt response to symptoms, testing for high-risk individuals and recent international travelers, getting vaccinated and improving indoor ventilation. Recalling difficulties caused by last summer's surge, the association emphasized that preventive habits such as hand-washing and mask-wearing remain crucial.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store